Holds one valid CEP for olmesartan medoxomil, filing since 2024. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 15 markets.
Holds 2 valid CEPs for olmesartan medoxomil, filing since 2024. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds 2 valid CEPs for olmesartan medoxomil, filing since 2025. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds one valid CEP for olmesartan medoxomil, filing since 2026. Its 2026 FDA inspection closed as NAI, and its GMP is recognised in 20 markets.
Holds 2 valid CEPs for olmesartan medoxomil, filing since 2026. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds one valid CEP for olmesartan medoxomil, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds 2 valid CEPs for olmesartan medoxomil, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 20 markets.
Registered with SFDA (Saudi Arabia) for olmesartan medoxomil. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 40 markets.
Holds one valid CEP for olmesartan medoxomil, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds 2 valid CEPs for olmesartan medoxomil, filing since 2025. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one valid CEP for olmesartan medoxomil, filing since 2021. Its 2025 FDA inspection closed as VAI.
Holds one valid CEP for olmesartan medoxomil, filing since 2022. Its 2019 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds one valid CEP for olmesartan medoxomil, filing since 2025. Its 2024 FDA inspection closed as VAI.
Holds one valid CEP for olmesartan medoxomil, filing since 2024. Its 2023 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one valid CEP for olmesartan medoxomil, filing since 2025. Its 2019 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one valid CEP for olmesartan medoxomil, filing since 2025. Its 2025 FDA inspection closed as VAI.
Holds one valid CEP for olmesartan medoxomil, filing since 2021. Its GMP is recognised in 9 markets.
Holds 4 valid CEPs for olmesartan medoxomil, filing since 2024.
Holds 2 valid CEPs for olmesartan medoxomil, filing since 2025.
Holds one valid CEP for olmesartan medoxomil, filing since 2026.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free| Year | Median | Exporters |
|---|---|---|
| 2026 YTD | $201.03 | 12 |
| 2025 | $303.99 | 33 |
| 2024 | $302.93 | 20 |
| 2023 | $485.57 | 23 |
US dollars per kilogram, customs export unit values.